Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q1 FY23 Earnings Presentation
19 slides from Jubilant Pharmova's earnings presentation, Aug 2, 2022
Slide 1: Financial Results Quarter Ended June 30, 2022
Financial Results Quarter Ended June 30, 2022
Slide 2: Conference Call Details
Conference Call Details Date : Aug 02, 2022 Time : 05:00 pm IST +91 22 6280 1141 Primary Number +91 22 7115 8042 USA: 1 866 746 2133 UK: 0 808 101 1573 Toll Free Number Singapore: 800 101 2045 Hong Kong: 800 964 448 Replay: Aug 02 to Aug 09, 2022 Dial-in: +91 22 7194 5757 / +91 22 6663 5757 Playback
Slide 3: Chairmen's Message
Chairmen’s Message Jubilant Pharmova Q1 FY23 Key Financial Parameters Particulars1 Q1'FY22 Q4'FY22 Q1'FY23 Total Revenue from Operations 1,635 1,528 1,452 Reported EBITDA 379 237 204 Reported EBITDA margin (%) 23.2% 15.5% 14.0% Profit After Tax 161 52 47 PAT margin (%) 9.8% 3.4% 3.2% EPS (Rs) 10.1 3
Slide 4: Update on API Demerger
Update on API Demerger In July 2021, the Board of Directors of Jubilant Pharmova Limited (JPM) approved demerger of the Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Limited(JGL) and vesting of the same with JPM, on a going concern basis, to be implemented through a sche
Slide 5: Jubilant Pharmova Reporting Segments Restructuring
Jubilant Pharmova Reporting Segments Restructuring S. No. SEBI Reporting Segments – Previous Structure S. No. SEBI Reporting Segments – Revised Structure 1 Pharmaceuticals 1 Radiopharma 2 Contract Research and Development Services 2 Allergy Immunotherapy 3 Proprietary Novel Drugs 3 CDMO Sterile Inje
Slide 6: Q1'FY23 Results Analysis
4 IBILANT Spence Q1'FY23 Results Analysis
Slide 7: Financial Highlights – Q1'FY23
Financial Highlights – Q1'FY23 Particulars1 Q1'FY22 Q4'FY22 Q1'FY23 Revenue was at Rs 1,452 Crore vs. Rs 1,635 Crore in Q1'FY22 and Rs 1,528 Total Revenue from Operations 1,635 1,528 1,452 Crore in Q4’FY22 Reported EBITDA 379 237 204 Depreciation and Amortisation 88 101 95 Reported EBITDA at Rs
Slide 8: Specialty Pharmaceuticals Segment Highlights – Q1'FY23
Specialty Pharmaceuticals Segment Highlights – Q1'FY23 Particulars1,2 Q1'FY22 Q4'FY22 Q1'FY23 Specialty Pharmaceuticals Total Revenue 632 695 722 a) Radiopharma 518 566 592 Revenue at Rs 722 Crore vs. Rs 632 Crore in Q1'FY22 and Rs 695 Crore in i) Radiopharmaceuticals 189 224 196 Q4’FY22. Over 9
Slide 9: CDMO Sterile Injectables Segment Highlights – Q1'FY23
CDMO Sterile Injectables Segment Highlights – Q1'FY23 Particulars1,2 Q1'FY22 Q4'FY22 Q1'FY23 CDMO Sterile Injectables’ revenue at Rs 263 Crore vs. Rs 373 Crore in Revenue 373 288 263 Q1'FY22 and Rs 288 Crore in Q4’FY22. Over 85% of the sales come from EBITDA 216 78 132 North America with balance f
Slide 10: CRDMO Segment Highlights – Q1'FY23
CRDMO Segment Highlights – Q1'FY23 Particulars1,2 Q1'FY22 Q4'FY22 Q1'FY23 CRDMO Total Revenue 193 318 280 a) Drug Discovery Services 88 142 118 Revenue at Rs 280 Crore vs. Rs 193 Crore in Q1'FY22 and Rs 318 Crore b) CDMO - API 105 176 162 in Q4’FY22 Reported EBITDA 53 73 46 EBITDA at Rs 46 Cro
Slide 11: Generics Segment Highlights – Q1'FY23
Generics Segment Highlights – Q1'FY23 Particulars1 Q1'FY22 Q4'FY22 Q1'FY23 Generics revenue at Rs 178 Crore vs. Rs 432 Crore in Q1'FY22 and Rs 221 Revenue 432 221 178 Crore in Q4’FY22 Reported EBITDA 53 (24) (74) Reported EBITDA Margin 12% (11%) (41%) Revenue and profitability lower vs. Q1’FY22
Slide 12: Jubilant Therapeutics: Clinical stage precision therapeutics company
Jubilant Therapeutics: Clinical stage precision therapeutics company addressing significant unmet medical needs in oncology and autoimmune diseases 11 11
Slide 13: Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases
Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases 12 12
Slide 14: Debt Profile
Debt Profile Particulars 31-03-22 30-06-22 Gross Debt (Rs. Crs) (Rs. Crs) Long Term 2,874 2,986 Short Term 64 109 Total 2,938 3,095 Cash & Equivalent 984 1,027 Net Debt (On a Constant Currency Basis) 1,954 1,951 Net Debt (constant currency) at Rs 1,951 Crore as on June 30, 2022 vs Rs 1,954 Crore a
Slide 15: Key Business Priorities
Key Business Priorities Radiopharmaceuticals Continued ramping up of Ruby-Fill installations New Product Development and Filings (atleast 2 New Products in FY-24) Radiopharma Timely execution of MIBG roadmap to enable FY-25 launch Radiopharmacies Focus on launch of new products to gain signi
Slide 16: Business outlook
Business outlook Speciality Pharmceuticals: In radiopharma, we continue to build a long term pipeline of diagnostic and therapeutic radiopharmaceuticals and are executing a turnaround plan of radiopharmacies, which is showing encouraging results. I131 MIBG clinical trials underway with launch expe
Slide 17: Appendix
a Es ¥ oa (o) VA A p pend IX 16
Slide 18: Income Statement – Q1'FY23
Income Statement – Q1’FY23 Particulars1 Q1'FY22 Q4'FY22 Q1'FY23 Revenue from Operations Specialty Pharmaceuticals 632 695 722 CDMO Sterile Injectables 373 288 263 Generics 432 221 178 Contract Research Development and Manufacturing Organisation 193 318 280 Proprietary Novel Drugs 0 0 4 Unallocable C
Slide 19: For more information
For more information For Investors: Vineet V Mayer Siddharth Rangnekar Ph: +91 120 436 1103 CDR India E-mail: vineet.mayer@jubl.com Ph: +91 +91 9769919966 E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Clayton Dsouza Ph: +91 120 436 1062 Madison Public Relations E-mail: sudhakar.safaya@j